Archive · 26 Jul 2026
US Tariffs Threaten India's Pharma Dominance
The US has announced new tariffs on generic medicines imported from India.
These tariffs will start at 0% until August 2028, then increase to 100% for one year, and finally to 200%.
India is a major supplier of generic drugs to the US, providing about 40% of its generic medicines.
This change could make medicines more expensive in the US and force Indian companies to either move their production to the US or find new markets.
Indian companies are considering investing in US manufacturing or diversifying their exports to other regions.
The US healthcare system relies heavily on these affordable Indian drugs, so the tariffs could lead to higher costs and potential shortages.
Both countries are discussing ways to manage this situation.
US announces phased tariffs on Indian generic medicines, starting at 0% until August 2028, then increasing to 100% and 200%.
India supplies 40% of US generic medicines, with $9.7 billion in exports to the US in 2025.
US healthcare system saves billions annually from Indian generics, but tariffs could disrupt supply and increase costs.
Indian pharma companies are exploring options like investing in US manufacturing or diversifying export markets.
The tariffs pose significant financial risks to Indian companies, potentially leading to consolidation in the sector.
- Who
- US President Donald Trump, Indian pharmaceutical companies
- What
- Implementation of phased tariffs on imported generic medicines from India
- When
- Announced on July 21, 2026, with phased implementation starting August 1, 2028
- Where
- United States and India
- Why
- To encourage domestic manufacturing and reduce dependency on foreign pharmaceuticals
US Trade Protectionism
Indian Pharma Resilience
Tariff Impact
US Trade Protectionism
The US aims to reduce dependency on foreign pharmaceuticals and boost domestic manufacturing.
Indian Pharma Resilience
Indian pharma companies face significant financial strain and potential market loss.
Market Adaptation
US Trade Protectionism
The US government encourages domestic production through tariffs and incentives.
Indian Pharma Resilience
Indian companies must invest in US manufacturing or diversify export markets to mitigate losses.
- Tariff Phases
- Zero until August 2028, 100% for one year, 200% thereafter
- US Reliance on Indian Generics
- Approximately 40% of US generic medicines are imported from India
- Indian Pharma Exports to US
- $9.7 billion in 2025, 38% of global pharma exports
- US Savings from Indian Generics
- $219 billion in 2022, $1.3 trillion from 2013-2022
- Key Indian Pharma Companies
- Sun Pharma, Aurobindo, Cipla, Dr. Reddy’s, Gland Pharma
